Growth inhibition of human hepatocellular carcinoma cells by antagonism of the β2 adrenergic receptor

Dang,Dongmei; Zhang,Jing; Yang,Jianjun

doi:10.3892/ol.2018.8847

Growth inhibition of human hepatocellular carcinoma cells by antagonism of the β2 adrenergic receptor

Authors:
- Dongmei Dang
- Jing Zhang
- Jianjun Yang
View Affiliations

Affiliations: Department of Pathogen Biology, Medical College of Yan'an University, Yan'an, Shaanxi 716000, P.R. China, Department of Genetics, Medical College of Yan'an University, Yan'an, Shaanxi 716000, P.R. China, Department of Interventional Radiology, Affiliated Hospital of Yan'an University, Yan'an, Shaanxi 716000, P.R. China
Published online on: May 31, 2018 https://doi.org/10.3892/ol.2018.8847
Pages: 1425-1430
Copyright: © Dang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous studies have shown that the activation of the β2 adrenergic receptor (ADRB2) can stimulate several signaling pathways that promote tumor growth and metastasis. β‑adrenergic antagonism may have a beneficial role in cancer treatment; however, little is known about the effect of ADRB2 inhibition on the growth of human hepatocellular carcinoma (HCC) cells. The present study revealed that ADRB2 was highly expressed in HCC cell lines compared with that in a normal liver cell line. Treatment with the ADRB2 antagonists ICI118,551 and metoprolol significantly inhibited the growth of human HCC cells. Annexin V/propidium iodide apoptosis and Hoechst staining assays revealed that treatment with ADRB2 antagonists induced apoptosis in HCC cells. Additionally, cell cycle analysis using propidium iodide staining demonstrated that growth suppression was associated with G2/M phase cell cycle arrest by ADRB2 antagonism in HCC cells. Treatment with the ADRB2 antagonists suppressed HCC growth, possibly through inhibiting expression of B‑cell lymphoma‑2 (Bcl‑2) and upregulating that of caspase‑9 and Bcl‑2‑associated X, as well as downregulating the expression levels of the G2/M phase‑associated proteins cyclin B1 and cyclin‑dependent kinase 1. Therefore, the observations of the present study indicate that ADRB2 blockade inhibited HCC growth, potentially mediated by inducing apoptosis and G2/M phase cell cycle arrest. ADRB2 antagonists may therefore be a promising therapeutic strategy for HCC.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	El-Serag HB: Hepatocellular carcinoma. N Engl J Med. 365:1118–1127. 2011. View Article : Google Scholar : PubMed/NCBI
3	Artinyan A, Mailey B, Sanchez-Luege N, Khalili J, Sun CL, Bhatia S, Wagman LD, Nissen N, Colquhoun SD and Kim J: Race, ethnicity, and socioeconomic status influence the survival of patients with hepatocellular carcinoma in the United States. Cancer. 116:1367–1377. 2010. View Article : Google Scholar : PubMed/NCBI
4	Antoni MH, Lutgendorf SK, Cole SW, Dhabhar FS, Sephton SE, McDonald PG, Stefanek M and Sood AK: The influence of bio-behavioural factors on tumour biology: Pathways and mechanisms. Nat Rev Cancer. 6:240–248. 2006. View Article : Google Scholar : PubMed/NCBI
5	Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, Jennings NB, Armaiz-Pena G, Bankson JA, Ravoori M, et al: Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med. 12:939–944. 2006. View Article : Google Scholar : PubMed/NCBI
6	Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, Choi HJ, Kuhn P, Weis WI, Kobilka BK and Stevens RC: High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science. 318:1258–1265. 2007. View Article : Google Scholar : PubMed/NCBI
7	Hara MR, Kovacs JJ, Whalen EJ, Rajagopal S, Strachan RT, Grant W, Towers AJ, Williams B, Lam CM, Xiao K, et al: A stress response pathway regulates DNA damage through β2-adrenoreceptors and β-arrestin-1. Nature. 477:349–353. 2011. View Article : Google Scholar : PubMed/NCBI
8	Quốc Lu'o'ng KV and Nguyễn LT: The roles of beta-adrenergic receptors in tumorigenesis and the possible use of beta-adrenergic blockers for cancer treatment: Possible genetic and cell-signaling mechanisms. Cancer Manag Res. 4:431–445. 2012.PubMed/NCBI
9	Cole SW and Sood AK: Molecular pathways: Beta-adrenergic signaling in cancer. Clin Cancer Res. 18:1201–1206. 2012. View Article : Google Scholar : PubMed/NCBI
10	Barron TI, Connolly RM, Sharp L, Bennett K and Visvanathan K: Beta blockers and breast cancer mortality: A population-based study. J Clin Oncol. 29:2635–2644. 2011. View Article : Google Scholar : PubMed/NCBI
11	Melhem-Bertrandt A, Chavez-Macgregor M, Lei X, Brown EN, Lee RT, Meric-Bernstam F, Sood AK, Conzen SD, Hortobagyi GN and Gonzalez-Angulo AM: Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol. 29:2645–2652. 2011. View Article : Google Scholar : PubMed/NCBI
12	Shan T, Ma Q, Zhang D, Guo K, Liu H, Wang F and Wu E: β2-adrenoceptor blocker synergizes with gemcitabine to inhibit the proliferation of pancreatic cancer cells via apoptosis induction. Eur J Pharmacol. 665:1–7. 2011. View Article : Google Scholar : PubMed/NCBI
13	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
14	Kassahun WT, Guenl B, Ungemach FR, Jonas S and Abraham G: Expression and functional coupling of liver β2-adrenoceptors in the human hepatocellular carcinoma. Pharmacology. 89:313–320. 2012. View Article : Google Scholar : PubMed/NCBI
15	Katritch V, Cherezov V and Stevens RC: Structure-function of the G protein-coupled receptor superfamily. Annu Rev Pharmacol Toxicol. 53:531–556. 2013. View Article : Google Scholar : PubMed/NCBI
16	Pérez-Sayáns M, Somoza-Martin JM, Barros-Angueira F, Diz PG, Gándara Rey JM and García-García A: Beta-adrenergic receptors in cancer: Therapeutic implications. Oncol Res. 19:45–54. 2010. View Article : Google Scholar : PubMed/NCBI
17	Weddle DL, Tithoff P, Williams M and Schuller HM: Beta-adrenergic growth regulation of human cancer cell lines derived from pancreatic ductal carcinomas. Carcinogenesis. 22:473–479. 2001. View Article : Google Scholar : PubMed/NCBI
18	Zhang D, Ma QY, Hu HT and Zhang M: β2-adrenergic antagonists suppress pancreatic cancer cell invasion by inhibiting CREB, NFκB and AP-1. Cancer Biol Ther. 10:19–29. 2010. View Article : Google Scholar : PubMed/NCBI
19	Pérez Piñero C, Bruzzone A, Sarappa MG, Castillo LF and Lüthy IA: Involvement of α2- and β2-adrenoceptors on breast cancer cell proliferation and tumour growth regulation. Br J Pharmacol. 166:721–736. 2012. View Article : Google Scholar : PubMed/NCBI
20	Toll L, Jimenez L, Waleh N, Jozwiak K, Woo AY, Xiao RP, Bernier M and Wainer IW: {Beta}2-adrenergic receptor agonists inhibit the proliferation of 1321N1 astrocytoma cells. J Pharmacol Exp Ther. 336:524–532. 2011. View Article : Google Scholar : PubMed/NCBI
21	Zhang D, Ma Q, Wang Z, Zhang M, Guo K, Wang F and Wu E: β2-adrenoceptor blockage induces G1/S phase arrest and apoptosis in pancreatic cancer cells via Ras/Akt/NFκB pathway. Mol Cancer. 10:1462011. View Article : Google Scholar : PubMed/NCBI
22	Liao X, Che X, Zhao W, Zhang D, Bi T and Wang G: The β-adrenoceptor antagonist, propranolol, induces human gastric cancer cell apoptosis and cell cycle arrest via inhibiting nuclear factor κB signaling. Oncol Rep. 24:1669–1676. 2010.PubMed/NCBI
23	Schuller HM: Mechanisms of smoking-related lung and pancreatic adenocarcinoma development. Nat Rev Cancer. 2:455–463. 2002. View Article : Google Scholar : PubMed/NCBI